Physician profile
Roxana Carcelen
NPI 1306801543
$6,935.77
in general payments reported to CMS, 2019-2025
28 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $441 · 2021: $1,133 · 2022: $2,268 · 2023: $710 · 2024: $555 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608 · Travel and Lodging: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.46 |
| Travel and Lodging | $972.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,734.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $1,489.98 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $1,165.64 | 2019-2024 | Breztri, Symbicort, Fasenra |
| Regeneron Healthcare Solutions, INC. | $515.83 | 2021-2024 | Dupixent |
| Grifols USA, LLC | $374.57 | 2020-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.15 | 2019-2023 | Ofev |
| Genzyme Corporation | $168.34 | 2022-2024 | |
| Genentech USA, INC. | $151.88 | 2019-2022 | |
| Harmony Biosciences LLC | $133.70 | 2020-2024 | |
| Electromed, INC. | $112.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.94 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $102.43 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $87.66 | 2021-2022 | |
| Mylan Specialty L.P. | $77.75 | 2021-2023 | Yupelri |
| Philips North America LLC | $69.95 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.76 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $59.95 | 2019 | |
| Baxter Healthcare | $34.88 | 2022 | |
| Merck Sharp & Dohme LLC | $34.27 | 2021-2023 | Belsomra |
| Axsome Therapeutics, INC. | $33.86 | 2023 | Sunosi |
| 3b Medical, INC. | $31.15 | 2024 | Luna |
| Amgen INC. | $29.38 | 2021-2023 | Tezspire |
| Circassia INC. | $19.24 | 2019 | |
| Advanced Respiratory, INC | $16.69 | 2021 | |
| Boston Scientific Corporation | $15.78 | 2024 | Spyglass Discover |
| Pulmonx Corporation | $13.51 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.34 | 2022 | |
| Inogen, INC. | $10.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxana Carcelen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.